UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of: May, 2005
Commission File Number: 000-50393
NEUROCHEM INC.
275 Armand-Frappier Boulevard
Laval, Quebec
H7V 4A7
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40 F. Form 20-F [ ] Form 40-F [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Yes [ ] No [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Yes [ ] No [X]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g-3 under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES:
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
NEUROCHEM INC.
May 20, 2005
By: /s/ David Skinner
---------------------------------------
David Skinner
General Counsel and Corporate Secretary
NEUROCHEM INC.
275 Armand-Frappier Blvd.
[NEUROCHEM LOGO] Laval, Quebec, Canada H7V 4A7
- --------------------------------------------------------------------------------
FOR FURTHER INFORMATION, PLEASE CONTACT:
Lise Hebert, PhD
Vice President, Corporate Communications
Tel: (450) 680-4572
lhebert@neurochem.com
NEUROCHEM TO PRESENT AT
UBS GLOBAL PHARMACEUTICALS CONFERENCE AND AT
FOURTH ANNUAL NEEDHAM BIOTECHNOLOGY CONFERENCE
MONTREAL, CANADA, MAY 19, 2005 -- Neurochem Inc. (NASDAQ: NRMX; TSX: NRM)
announced today that on May 24, 2005, Francesco Bellini, PhD, Chairman,
President and CEO, will present Neurochem's overall strategy and progress to
date at the UBS Global Pharmaceuticals Conference to be held at the Grand Hyatt
Hotel, in New York City. The presentation will take place at 3:00 P.M. ET, in
Ballroom D, Ballroom Level. Following Dr. Bellini's speech, the corporate
presentation will be available on the Company's website at
http://www.neurochem.com/Investor.htm#Presentation.
A live audio webcast of Neurochem's presentation can also be accessed at
www.ibb.ubs.com This webcast will be available for 30 days through to June 23,
2005.
Dr. Lise Hebert, Neurochem's Vice President, Corporate Communications, will also
present the Company's overall strategy and progress to date at the Fourth Annual
Needham Biotechnology Conference on May 25, 2005, at the New York Palace Hotel.
Her presentation will take place at 10:00 A.M. and will also be available on the
Company's website.
ABOUT NEUROCHEM
Neurochem is focused on the development and commercialization of innovative
therapeutics for neurological disorders. The Company's pipeline of proprietary,
disease-modifying oral products addresses critical unmet medical needs.
1,3-propanedisulfonate (1,3PDS; Fibrillex(TM)) is designated as an orphan drug
and a Fast Track Product candidate and is also part of an FDA Continuous
Marketing Applications Pilot 2 program. The Phase II/III clinical trial of
Fibrillex(TM) for the treatment of AA Amyloidosis was recently concluded and
preliminary results were disclosed in April 2005. 3-amino-1-propanesulfonic acid
(3APS; Alzhemed(TM)), for the treatment of Alzheimer's Disease, is in a Phase
III clinical trial and 3APS (Cerebril(TM)), for the prevention of Hemorrhagic
Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical
trial.
TO CONTACT NEUROCHEM
For additional information on Neurochem and its drug development programs,
please call the North American toll-free number 1 877 680-4500 or visit our Web
Site at: www.neurochem.com.
Certain statements contained in this news release, other than statements of fact
that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties,
known and unknown, many of which are beyond Neurochem's control. Such risks
include but are not limited to: the impact of general economic conditions,
general conditions in the pharmaceutical industry, changes in the regulatory
environment in the jurisdictions in which Neurochem does business, stock market
volatility, fluctuations in costs, and changes to the competitive environment
due to consolidation, as well as other risks disclosed in public filings of
Neurochem. Consequently, actual future results may differ materially from the
anticipated results expressed in the forward-looking statements. The reader
should not place undue reliance, if any, on the forward-looking statements
included in this news release. These statements speak only as of the date made
and Neurochem is under no obligation and disavows any intention to update or
revise such statements as a result of any event, circumstances or otherwise.